Business Wire

FDA grants IPS HEART Orphan Drug Designation for GIVI-MPC for Treatment of Duchenne Muscular Dystrophy

HOUSTON--(BUSINESS WIRE)--IPS HEART has been granted orphan drug designation by the FDA for GIVI-MPC, a first-in-class stem cell therapeutic to create new skeletal muscle with 100% full length ...
Business Wire

FDA Grants Orphan Drug Designation to IPS HEART’s GIVI-MPC Stem Cell Therapy for Becker Muscular Dystrophy

HOUSTON--(BUSINESS WIRE)--IPS HEART has been awarded Orphan Drug Designation (ODD) by the FDA for GIVI-MPCs based on its unique ability to create new muscle with full length dystrophin in Becker ...
BioWorld

Ips Heart’s stem cell therapy designated orphan drug for Becker muscular dystrophy

Ips Heart Inc. has been awarded orphan drug designation by the FDA for its GIVI-MPC stem cell therapy for Becker muscular dystrophy. GIVI-MPC has the unique ability to create new muscle with full ...